Keyphrases
First-line Therapy
100%
Metastatic Renal Cell Carcinoma (mRCC)
100%
Efficacy Comparison
100%
Propensity Score Matching
100%
Matched Comparison
100%
Immune Checkpoint Inhibitors
100%
Tyrosine Kinase Inhibitor
30%
Treatment-related Adverse Events
15%
Progressive Disease
7%
Progression-free Survival
7%
Clear Cell Renal Cell Carcinoma (ccRCC)
7%
Objective Response Rate
7%
Disease Rate
7%
Inhibitor Combination
7%
Score-based
3%
Combination Therapy
3%
Systemic Treatment
3%
Pharmacological Activities
3%
Clinical Behavior
3%
Median Progression-free Survival
3%
Median Overall Survival
3%
Disease Treatment
3%
Risk Classification
3%
Clinical Decision-making
3%
Propensity Score
3%
Overall Survival Benefit
3%
Overall Survival Progression-free Survival
3%
Matching Process
3%
Matched Cohort
3%
Sequential Therapy
3%
Immune Checkpoint Inhibitor Combinations
3%
Pharmacology, Toxicology and Pharmaceutical Science
Kidney Metastasis
100%
Immune Checkpoint Inhibitor
100%
Protein Tyrosine Kinase Inhibitor
29%
Adverse Event
14%
Progression Free Survival
14%
Overall Survival
11%
Diseases
7%
Systemic Treatment
3%
Combination Therapy
3%
Drug Action
3%